"System readiness and the patient care pathway for Alzheimer's disease " by B Joy Snider, Alessandro Biffi et al.
 

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment

Authors

B Joy Snider, Department of Neurology Washington University School of Medicine St. Louis Missouri USA.
Alessandro Biffi, Eli Lilly and Company Indianapolis Indiana USA.
Sasha Bozeat, F. Hoffman-La Roche AG Basel Switzerland.
Carolyn Clevenger, Nell Hodgson Woodruff School of Nursing Emory University Atlanta Georgia USA.
Gill Farrar, GE HealthCare Buckinghamshire UK.
Darren Gitelman, Advocate Health - MidwestFollow
Rachel Kolster, The Janssen Pharmaceutical Companies of Johnson & Johnson Titusville New Jersey USA.
Soeren Mattke, The USC Brain Health Observatory USC Dornsife Los Angeles California USA.
Michelle Mielke, Division of Public Health Sciences Wake Forest University School of Medicine Winston-Salem North Carolina USA.
Debjani Mukherjee, Pharmaceutical Care Management Association Washington District of Columbia USA.
Jennifer Murphy, Biogen Neurodegeneration Unit Cambridge Massachusetts USA.
Hamid Okhravi, Department of Medicine: Glennan Center for Geriatrics and Gerontology Eastern Virginia Medical School Norfolk Virginia USA.
Gil D. Rabinovici, Memory & Aging Center Departments of Neurology Radiology & Biomedical Imaging, University of California San Francisco San Francisco California USA.
Dorene Rentz, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts USA.
Jose Soria, University of California San Diego Health San Diego California USA.
Heather Synder, Alzheimer's Association Chicago Illinois USA.
Gregg Walker, Alzheimer's Association Chicago Illinois USA.
Simin Mahinrad, Alzheimer's Association Chicago Illinois USA.
Maria C. Carrillo, Alzheimer's Association Chicago Illinois USA.
Christopher J. Weber, Alzheimer's Association Chicago Illinois USA.

Affiliations

Advocate Lutheran General Hospital

Abstract

Promising therapeutic interventions that target the underlying pathophysiology are changing the landscape of Alzheimer's disease (AD) research. The AD care pathway must be transformed to meet the challenge of bringing these new therapies to the increasing number of people living with AD within the existing healthcare framework. Challenges include identifying patients who may benefit from treatment interventions early in the course of the disease, ensuring that diagnostic tools are accessible and accurate, and developing capabilities to monitor the effectiveness of interventions over time. These challenges must be addressed at all levels, from primary care settings to tertiary treatment centers; this will require collaborative efforts between health systems, drug manufacturers, and research institutions to navigate this evolving landscape and ensure system readiness for patients and their families with AD. The Spring 2024 Alzheimer's Association Research Roundtable (AARR) meeting gathered industry representatives and clinicians to discuss insights, challenges, and solutions that will help researchers and health systems identify patients in the early stages of AD and deliver emerging therapies efficiently and safely. In this paper, we provide highlights from the Spring 2024 AARR meeting.

Type

Article

PubMed ID

40547330


 

Share

COinS